Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.61 |
| ▸ | CTSS | P25774 | 6/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182119 | 1.00 | CTSK (0.61) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL29877959 | 1.00 | CTSK (0.61) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL356447 | 0.88 | CTSK (0.53) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL14488100 | 0.87 | TACR1 (0.55) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL17039822 | 0.87 | TACR1 (0.55) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL5689118 | 0.87 | TACR1 (0.55) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL11301054 | 0.87 | CASP1 (0.50) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL11288027 | 0.86 | CTSK (0.54) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL356213 | 0.86 | CTSK (0.54) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL45092 | 0.86 | CTSK (0.47) | CTSKCTSSCTSLCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289660-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-09-15 | — | — | US | disclosed |
| US-11365216-B2 | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | PVP LABS PTE. LTD. (SG) | 2022-06-21 | — | — | US | disclosed |
| US-20220024845-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-10947177-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200181057-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190345091-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20180141891-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2018-05-24 | — | — | US | disclosed |
| EP-2792353-B1 | Polymorph of Treprostinil diethanolamine salt | UNITED THERAPEUTICS CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9878972-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-9624156-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-4698329-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
| US-4517119-A | Synthesis of thymosin α1 | HOFFMANN-LA ROCHE INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-4504415-A | Synthesis of thymosin α1 and desacetyl thymosin α1 | HOFFMAN-LA ROCHE INC. (US) | 1985-03-12 | — | — | US | disclosed |
| EP-0123951-A2 | Intermediates for thymosin alpha 1 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-11-07 | — | — | EP | disclosed |
| EP-0123950-A2 | Intermediates for thymosin alpha 1 and desacetylthymosin alpha 1 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-11-07 | — | — | EP | disclosed |
| US-4401594-A | PROTEOLYTIC ENZYME INHIBIJTORS; CARDIOVASCULAR AND MUSCULAR DISORDERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | disclosed |
| US-4264590-A | DIPEPTIDE OF A HALOALANINE | ABBOTT LABORATORIES (US) | 1981-04-28 | — | — | US | disclosed |
| EP-0000063-A1 | Dipeptide derivatives of 7-(N-alpha-substituted or non-substituted X-arginyl)-amino-4-methyl-coumarin | AJINOMOTO CO., INC. (JP) | 1978-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289660-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | CTSK 974/4885CTSS 1278/4885CTSL 1202/4885 |
| US-20220024845-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | CTSK 974/4885CTSS 1278/4885CTSL 1202/4885 |
| US-10947177-B2 | Compounds and methods for delivery of prostacyclin analogs | PTGIR, PTGIS, PGF | CTSK 964/4885CTSS 1139/4885CTSL 1179/4885 |
| US-20190345091-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | CTSK 964/4885CTSS 1139/4885CTSL 1179/4885 |
| US-20180141891-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | CTSK 964/4885CTSS 1139/4885CTSL 1179/4885 |
| US-20200181057-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | CTSK 964/4885CTSS 1139/4885CTSL 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.